IL-17 and IL-22 serum cytokine levels in patients with squamous intraepithelial lesion and invasive cervical carcinoma

European Journal of Gynaecological Oncology

Volumn 34, Issue 5, 2013, Pages 466-468

  Souza, J M ^a   Matias, B F ^a   Rodrigues, C M ^a   Murta, E F C ^a   Michelin, M A ^a  

^a FEDERAL UNIVERSITY OF TRIÂNGULO MINEIRO   (Brazil)

Author keywords

Antitumor response; Immune response; Squamous intraepithelial lesions; Th17 lymphocytes

Indexed keywords

INTERLEUKIN 17; INTERLEUKIN 22;

ARTICLE; CANCER PATIENT; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INVASIVE CARCINOMA; INVASIVE CERVICAL CARCINOMA; MAJOR CLINICAL STUDY; PROTEIN BLOOD LEVEL; SQUARNOUS INTRAEPITHELIAL LESION; UTERINE CERVIX CARCINOMA;

CERVICAL INTRAEPITHELIAL NEOPLASIA; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN-17; INTERLEUKINS; UTERINE CERVICAL NEOPLASMS;

EID: 84888781069     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Mosmann T.R., Coffman R.L.: "TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties". Annu. Rev. Immunol., 1989, 7, 145.
2. Kidd P.: "Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease". Altern. Med. Rev., 2003, 8, 223.
3. Bettelli E., Kornm T., Oukka, M., Kuchroo V.K.: "Induction and effectors functions of TH17 cells". Nature, 2008, 453, 1051.
4. Elyaman W., Bradshaw E.M., Uyttenhove C.: "IL-9 induces differentiation of TH17 cells and enhances function of FoxP3+ natural regulatory T cells." Proc. Natl. Acad. Sci USA, 2009, 31, 12885.
5. Josefowicz S.Z., Rudensky A.: "Control of regulatory T cell lineage commitment and maintenance." Immunity. 2009, 30, 616-625.
6. H-2 cells". Nat. Immunol., 2009, 10, 864.
7. Glimcher L.H., Murphy K.M.: "Lineage commitment in the immune system: the T helper lymphocyte grows up". Genes Develop., 2000, 14, 1693.
8. Korn T., Bettelli E., Oukka M. Kuchroo V.K.: "IL-17 and Th17 cells". Anna. Rev. Immunol., 2009, 27, 485.
9. Kolls J.K., Linden A.: "Interleukin-17 family members and inflammation". Immunity, 2004, 21, 467.
10. Kryczek I., Wei S., Szeliga W., Vatan L., Zou W.: "Endogenous IL-17 contributes to reduced tumor growth and metastasis". Blood, 2009, 114, 357.
11. Numasaki M., Fukushi J., Ono M., Narula S.K., Zavodny P.J., Kudo T. et al.: "Interleukin-17 promotes angiogenesis and tumor growth". Blood 2003, 101, 2620.
12. Tartour E., Fossiez F., Joveux I., Galinha A., Gey A., Claret E. et al.: "Interleukin 17, a T-cell-derived Cytokine, Promotes Tumorigenicity of human cervical tumors in nude mice". Cancer Res., 1999, 59, 3698.
13. Xie M.H., Agganwal S., Ho W.H., Foster J., Zhang Z., Stinson J. et al.: "Interleukin (IL)-22, a novel human cytokine that signals through the interferon receptor-related proteins CRF2-4 and IL-22R". J. Biolog. Chem., 2000, 275, 31335.
14. Pestka S., Krause C.D., Sarkar D., Walter M.R., Shi Y., Fisher P.B.: "Interleukin-10 and related cytokines and receptors". Am. Rev. Immun., 2004, 22.929-22.979.
15. Ricciardi L., Minciullo P.L., Saitta S.,Trombetta D., Saija A., Gangemi S.: "Increased serum levels of IL-22 in patients with nickel contact dermatitis". Cont. Dermat., 2009, 60, 57.
16. Wolk K., Witte E., Wallace E., Döcke W.D., Kunz S., Asadullah K. et al.: "IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis". Eur. J. Immtmol., 2006, 36, 1309.
17. Spolski R., Leonard R.J.: "The yin and yang of interleukin-21 in allergy, autoimmunity and cancer". Curr. Opin. Immun., 2008, 20, 3, 295.
18. Miossec P.: "Clinical implications of Th17/IL-17". Eur. J. Immun., 2009, 39, 634.
19. Kenders M.I., Lubberts E., Oppers-Walgreen B., van den Bersselaar L., Helsen M.M., Di Padova F.E. et al.: "Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1". Am. J. Path., 2005, 167, 141.
20. Zheng Y., Danilenko D.M., Valdez P., Kasman I., Eastham-Anderson J., Wu J., Ouyang W.: "Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis". Nature, 2007, 445, 648.
21. Aujla S.J., Chan Y.R., Zheng M., Fei M., Askew D.J., Pociask D.A. et al.: "IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia". Nature Med., 2008, 14, 275.
22. Ouyang W., Filvarpff E., Hu Y., Grogan J.: "Novel therapeutic targets along the Th17 pathway". Eur. J. Immun., 2009, 39, 634.
23. Mcgeachy M.J., Cua D.J.: "Th17 cell differentiation: the long and winding road". Immunity, 2008, 28, 445.
24. Ouyang W., Kolls J. K., Zheng V.: "The biological functions of T helper 17 cell effector cytokines in inflammation". Immunity., 2008, 28, 454.
25. Östor A.G.: "Natural history of cervical intraepithelial neoplasia: A critical review". Int. J. Gynec. Path., 1993, 12, 186.
26. Zhu X., Mulcahy L.A., Mohammed A.R., Lee A.H., Franks H.A., Kilpatrick L. et al.: "IL-17 expression by breast-cancer-associated macrophages: IL-17 promotes invasiveness of breast cancer cell lines". Breast Cancer Res., 2008, 10, 95.
27. Gaffen S.L.: "An overview of IL-17 function and signaling". Cytokine, 2008, 43, 402.